300 related articles for article (PubMed ID: 25258407)
21. Effect of long-term, continuous versus alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis.
Ligumsky M; Lysy J; Siguencia G; Friedlander Y
J Clin Gastroenterol; 2001 Jul; 33(1):32-5. PubMed ID: 11418787
[TBL] [Abstract][Full Text] [Related]
22. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study.
Tsai CF; Chen MH; Wang YP; Chu CJ; Huang YH; Lin HC; Hou MC; Lee FY; Su TP; Lu CL
Gastroenterology; 2017 Jan; 152(1):134-141. PubMed ID: 27639806
[TBL] [Abstract][Full Text] [Related]
23. Urinary metabolic profiling by
McPhail MJ; Montagnese S; Villanova M; El Hadi H; Amodio P; Crossey MM; Williams R; Cox IJ; Taylor-Robinson SD
Metab Brain Dis; 2017 Apr; 32(2):331-341. PubMed ID: 27638475
[TBL] [Abstract][Full Text] [Related]
24. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients.
Bajaj JS; Sterling RK; Betrapally NS; Nixon DE; Fuchs M; Daita K; Heuman DM; Sikaroodi M; Hylemon PB; White MB; Ganapathy D; Gillevet PM
Aliment Pharmacol Ther; 2016 Sep; 44(6):638-43. PubMed ID: 27417456
[TBL] [Abstract][Full Text] [Related]
25. Celiac disease serology and gut microbiome following proton pump inhibitor treatment.
Jang S; Lebwohl B; Abrams JA; Green PHR; Freedberg DE; Alaedini A
Medicine (Baltimore); 2020 Aug; 99(35):e21488. PubMed ID: 32871870
[TBL] [Abstract][Full Text] [Related]
26. Alterations in Skin Microbiomes of Patients With Cirrhosis.
Bajaj JS; Fagan A; Sikaroodi M; Kakiyama G; Takei H; Degefu Y; Pandak WM; Hylemon PB; Fuchs M; John B; Heuman DM; Gavis E; Nittono H; Patil R; Gillevet PM
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2581-2591.e15. PubMed ID: 30905718
[TBL] [Abstract][Full Text] [Related]
27. Gut microbiota-related complications in cirrhosis.
Gómez-Hurtado I; Such J; Sanz Y; Francés R
World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
[TBL] [Abstract][Full Text] [Related]
28. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
[TBL] [Abstract][Full Text] [Related]
29. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.
Kakiyama G; Pandak WM; Gillevet PM; Hylemon PB; Heuman DM; Daita K; Takei H; Muto A; Nittono H; Ridlon JM; White MB; Noble NA; Monteith P; Fuchs M; Thacker LR; Sikaroodi M; Bajaj JS
J Hepatol; 2013 May; 58(5):949-55. PubMed ID: 23333527
[TBL] [Abstract][Full Text] [Related]
30. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
Paroni Sterbini F; Palladini A; Masucci L; Cannistraci CV; Pastorino R; Ianiro G; Bugli F; Martini C; Ricciardi W; Gasbarrini A; Sanguinetti M; Cammarota G; Posteraro B
Appl Environ Microbiol; 2016 Nov; 82(22):6633-6644. PubMed ID: 27590821
[TBL] [Abstract][Full Text] [Related]
31. Influence of proton pump inhibitors on microbiota in chronic liver disease patients.
Yamamoto K; Ishigami M; Honda T; Takeyama T; Ito T; Ishizu Y; Kuzuya T; Hayashi K; Goto H; Hirooka Y
Hepatol Int; 2019 Mar; 13(2):234-244. PubMed ID: 30737678
[TBL] [Abstract][Full Text] [Related]
32. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients.
Kim JW; Jeong Y; Park SJ; Jin H; Lee J; Ju JH; Ji GE; Park SH
Rheumatology (Oxford); 2021 Feb; 60(2):708-716. PubMed ID: 32789440
[TBL] [Abstract][Full Text] [Related]
33. Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress.
Karl JP; Margolis LM; Madslien EH; Murphy NE; Castellani JW; Gundersen Y; Hoke AV; Levangie MW; Kumar R; Chakraborty N; Gautam A; Hammamieh R; Martini S; Montain SJ; Pasiakos SM
Am J Physiol Gastrointest Liver Physiol; 2017 Jun; 312(6):G559-G571. PubMed ID: 28336545
[TBL] [Abstract][Full Text] [Related]
34. Fungal dysbiosis in cirrhosis.
Bajaj JS; Liu EJ; Kheradman R; Fagan A; Heuman DM; White M; Gavis EA; Hylemon P; Sikaroodi M; Gillevet PM
Gut; 2018 Jun; 67(6):1146-1154. PubMed ID: 28578302
[TBL] [Abstract][Full Text] [Related]
35. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids.
Jin M; Kalainy S; Baskota N; Chiang D; Deehan EC; McDougall C; Tandon P; Martínez I; Cervera C; Walter J; Abraldes JG
Liver Int; 2019 Aug; 39(8):1437-1447. PubMed ID: 30919578
[TBL] [Abstract][Full Text] [Related]
36. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore.
Koo SH; Deng J; Ang DSW; Hsiang JC; Lee LS; Aazmi S; Mohamed EHM; Yang H; Yap SY; Teh LK; Salleh MZ; Lee EJD; Ang TL
Singapore Med J; 2019 Oct; 60(10):512-521. PubMed ID: 30488079
[TBL] [Abstract][Full Text] [Related]
37. A Prospective, Placebo-Controlled Pilot Evaluation of the Effect of Omeprazole on Serum Calcium, Magnesium, Cobalamin, Gastrin Concentrations, and Bone in Cats.
Gould E; Clements C; Reed A; Giori L; Steiner JM; Lidbury JA; Suchodolski JS; Brand M; Moyers T; Emery L; Tolbert MK
J Vet Intern Med; 2016 May; 30(3):779-86. PubMed ID: 27062346
[TBL] [Abstract][Full Text] [Related]
38. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort.
Bajaj JS; Idilman R; Mabudian L; Hood M; Fagan A; Turan D; White MB; Karakaya F; Wang J; Atalay R; Hylemon PB; Gavis EA; Brown R; Thacker LR; Acharya C; Heuman DM; Sikaroodi M; Gillevet PM
Hepatology; 2018 Jul; 68(1):234-247. PubMed ID: 29350768
[TBL] [Abstract][Full Text] [Related]
39. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.
Shamsaddini A; Gillevet PM; Acharya C; Fagan A; Gavis E; Sikaroodi M; McGeorge S; Khoruts A; Albhaisi S; Fuchs M; Sterling RK; Bajaj JS
Gastroenterology; 2021 Aug; 161(2):508-521.e7. PubMed ID: 33857456
[TBL] [Abstract][Full Text] [Related]
40. Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis.
Cox IJ; Idilman R; Fagan A; Turan D; Ajayi L; Le Guennec AD; Taylor-Robinson SD; Karakaya F; Gavis E; Andrew Atkinson R; Williams R; Sikaroodi M; Nizam S; Gillevet PM; Bajaj JS
Liver Int; 2020 Feb; 40(2):416-427. PubMed ID: 31544308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
